Thank you very much, Madam Chair. It is nice to see you in the chair today.
Thanks, witnesses, for being with us today.
I want to refer back to one of the earlier witnesses as well, Dr. Andra Smith. She is a neuroscientist. This is referring to the Ottawa pre-natal study. Would you be familiar with that work, using functional MRI?
They follow these subjects right from birth through their adolescent years, but they quantify some very significant changes in blood flow with people, referring to the executive functions that are impaired in marijuana users and the delayed cognitive response, reasoning power, problem-solving, and decision-making, particularly in the case of adolescents. The younger they are when they start and the heavier the use, the greater the impairment.
It seems to me that would be of real concern, with Canada's youth being one of the highest user populations in the world. It speaks to the productivity of our country, which is important to some of us at the table here. We want citizens who are able to perform higher cognitive-function activities later in life. I wonder whether it is of concern to you that in fact the fMRI evidence shows that it is delaying myelination in the prefrontal cortex and shifting activities to the limbic system, where decisions are made more on an emotional basis; that people performing these tasks are actually taking longer to solve simple problems, and that this therefore perhaps leads to the anxiety that we're referring to.
I wonder whether you have any comment on that part of the scientific literature that is out there and those concerns?